Jazz Pharmaceuticals (JAZZ) is up 20.8%, or $29.41 to $170.48.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals Stock Surges on Positive Phase 3 Trial Results
- Promising HERIZON-GEA Trial Results Drive Buy Rating for Jazz Pharmaceuticals’ Ziihera
- Jazz Pharmaceuticals Announces Positive Phase 3 Trial Results
- Jazz Pharmaceuticals announces top-line results from HERIZON-GEA-01 trial
- Zymeworks’ Ziihera shows efficacy in Phase 3 adenocarcinoma trial